天然多亚型干扰素-αN1治疗慢性乙型肝炎的疗效观察  

An observation on antiviral effect of IFN-αN1(WELLFERON) in patients with chronic hepatitis B

作　　者：刘德恭[1,2] 温小凤[1,2] 孟庆华[1,2] 黄康玲 向海平 王竹生[1,2] 

机构地区：[1]北京佑安医院 [2]广西柳州市人民医院

出　　处：《中华实验和临床病毒学杂志》1998年第2期125-128,共4页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的观察干扰素的抗病毒作用。方法用天然多亚型干扰素－αＮ１（惠福仁）治疗５０例慢性乙型肝炎，另５０例为对照组，两组临床与实验室指标均有可比性。治疗组用ＩＦＮ－αＮ１３ＭｕＩＭｑｄ治疗７ｄ，继用３ＭｕＩＭｔｉｗ治疗１１～２３周。结果经３个月治疗，治疗组与对照组的丙氨酸转氨酶复常率分别为８４％（４２５０）和４６％（２３５０），Ｐ＜０．０１；ＨＢｅＡｇ阴转率为５６．７％（１７３０）和１０．８％（４３７）；ＨＢＶＤＮＡ的阴转率为３６．４％（１２３３）和５．９％（１１７），Ｐ＜０．０１。结论ＩＦＮ－αＮ１治疗慢性乙型肝炎是目前疗效比较满意的抗病毒药，且副作用少。In order to observe the antiviral effect of IFN-α N1(Wellferon,British Glaxowellcome Company)on CHB,each 50 cases of CHB were selected as the therapy group and the control group. The patiens in the therapy group were administrated with 3MU of IFN-αN1 once a day for one week,and then 3MU of IFN-αN1 three times weekly for 11～23 weeks, whereas the patients in the control group did not recieve any antiviral treatment.At 3 months, the serum alanine transaminsae(ALT) was decreased to normal level in 84%(4250)cases of the therapy group,while only in 46%(2350)cases of the control group (P<0.01).The negative seroconversion rate of HBeAg was 56.7%(1730)and 10.8%(437), of HBV DNA was 36.4%(1233) and 5.9%(117) in therapy and control groups respectively.There was abvious difference in two groups. The results suggest that IFN-αN1 is satisfying antiviral drug for CHB patients or patients non-responsive to other IFNs.

关 键 词：干扰素 乙型肝炎 HBSAG HBEAG 

分 类 号：R512.620.5[医药卫生—内科学]